Home / Community / News / News

News

02/24/2017 - 10:39am

Clinical trials involve substantial investments by drug developers, but especially by DM patients and families. Clinical trials proposed for our community must have adequate scientific rationale behind them.

02/24/2017 - 10:22am

MDF runs down some important changes in the purposes and rationale of NINDS funding mechanisms for postdoctoral fellows.

02/24/2017 - 9:59am

FDA released an online course to accompany their draft guidance on how to best communicate with the Agency in preparing and filing an IND.

02/24/2017 - 9:50am

Gene editing is a potential avenue for therapy development in DM. With the safety, efficacy and delivery challenges, how do we get there?

02/02/2017 - 2:54pm

When Dr. Thurman Wheeler was a resident in neurology, he remembers a senior physician telling him that myotonic dystrophy would probably be one of the most difficult diseases to treat because it involves so many body systems.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.